HC Wainwright reiterated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS - Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $30.00 target price on the stock.
Mineralys Therapeutics Stock Down 2.9 %
MLYS traded down $0.40 during trading hours on Thursday, hitting $13.38. The stock had a trading volume of 162,481 shares, compared to its average volume of 173,031. Mineralys Therapeutics has a 1 year low of $5.85 and a 1 year high of $16.91. The company's fifty day simple moving average is $12.69 and its 200 day simple moving average is $12.50. The stock has a market cap of $664.30 million, a PE ratio of -6.11 and a beta of 1.93.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). During the same period in the previous year, the firm posted ($0.31) EPS. As a group, equities analysts expect that Mineralys Therapeutics will post -3.08 EPS for the current year.
Insider Transactions at Mineralys Therapeutics
In other Mineralys Therapeutics news, CEO Jon Congleton sold 15,271 shares of Mineralys Therapeutics stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $13.52, for a total transaction of $206,463.92. Following the completion of the transaction, the chief executive officer now owns 895,941 shares of the company's stock, valued at $12,113,122.32. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Adam Scott Levy sold 10,757 shares of the stock in a transaction on Friday, October 11th. The stock was sold at an average price of $13.57, for a total value of $145,972.49. Following the sale, the chief financial officer now owns 236,854 shares in the company, valued at approximately $3,214,108.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jon Congleton sold 15,271 shares of Mineralys Therapeutics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.52, for a total value of $206,463.92. Following the sale, the chief executive officer now directly owns 895,941 shares of the company's stock, valued at $12,113,122.32. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 33.24% of the company's stock.
Hedge Funds Weigh In On Mineralys Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its position in shares of Mineralys Therapeutics by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock valued at $116,000 after buying an additional 3,732 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company's stock valued at $35,000 after acquiring an additional 4,099 shares during the last quarter. Vanguard Group Inc. raised its position in Mineralys Therapeutics by 0.5% during the first quarter. Vanguard Group Inc. now owns 982,932 shares of the company's stock valued at $12,690,000 after purchasing an additional 4,952 shares in the last quarter. Federated Hermes Inc. lifted its stake in Mineralys Therapeutics by 100.0% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock worth $140,000 after purchasing an additional 6,000 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Mineralys Therapeutics in the 3rd quarter worth about $110,000. 84.46% of the stock is currently owned by institutional investors.
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Further Reading
Before you consider Mineralys Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mineralys Therapeutics wasn't on the list.
While Mineralys Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
